RELATED CONTENT
August 25, 2011 — Bayer HealthCare Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational compound, radium-223 chloride, exclusively licensed from Algeta ASA. The compound is for the treatment of castration-resistant (hormone-refractory) prostate cancer in patients with bone metastases.
August 27, 2011 
March 15, 2011 – The U.S. Food and Drug Administration (FDA) has approved Gadavist (gadobutrol) injection, a macrocyclic gadolinium-based contrast agent (GBCA), for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children.
March 15, 2011 
January 8, 2009 – Bayer Schering Pharma AG and Hamamatsu Photonics K.K., Japan have signed a licensing agreement for the use of novel substances in the field of molecular imaging for cancer, allowing the company to expand its existing molecular imaging portfolio in the area of cancer.
January 08, 2009 
VistaTrak is a new a touchscreen contrast media management system that gives users a management tool designed to help enhance patient care and safety, optimize inventory management and improve billing accuracy.
May 20, 2008 Bayer Healthcare Pharmaceuticals responded to concerns by the Joint Commission on Accreditation of Healthcare ...
November 29, 2007 December 1, 2007 – Bayer Healthcare Pharmaceuticals previewed at RSNA 2007 VistaTrak, a password protected contrast ...
November 29, 2007 November 9, 2007 - Bayer HealthCare Pharmaceuticals announced that the company has been awarded a three-year contract ...
November 08, 2007